8-K: Alnylam Pharmaceuticals Q2 2026 Earnings Beat, Guidance Lowered

Alnylam Pharmaceuticals reported strong Q2 2026 results with significant revenue growth, but revised its full-year TTR net product revenue guidance downwards.

Summary

• Alnylam Pharmaceuticals announced its financial results for the second quarter ended June 30, 2026.
• Global net product revenues reached $1,172 million, a 74% increase compared to Q2 2025.
• Total TTR (Transthyretin-mediated amyloidosis) revenues were $1,030 million, up 89% year-over-year, driven by AMVUTTRA.
• Total Rare disease revenues (GIVLAARI and OXLUMO) were $142 million, an 11% increase.
• The company revised its full-year 2026 TTR net product revenue guidance downwards to $4,200 $4,500 million from $4,400 $4,700 million.
• This revision is attributed to learnings from the initial phase of the ATTR-CM market launch, specifically the normalization of growth in second-line volume after pent-up demand was satisfied.
• GAAP Net income was $164.5 million, or $1.21 per diluted share, compared to a net loss of $72.2 million, or ($0.55) per diluted share, in Q2 2025.
• Non-GAAP Net income was $251.8 million, or $1.84 per diluted share, a significant increase from $38.2 million, or $0.28 per diluted share, in Q2 2025.
• Cash, cash equivalents, and marketable securities stood at $3.3 billion as of June 30, 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, with strong Q2 performance and significant year-over-year growth, despite a cautious revision to full-year guidance.

Positives

• Strong Q2 2026 global net product revenues of $1,172 million, a 74% increase year-over-year.
• Significant growth in Total TTR net product revenues to $1,030 million, up 89% compared to Q2 2025, primarily driven by AMVUTTRA.
• Total Rare net product revenues increased by 11% to $142 million.
• Achieved first-time quarterly product revenues exceeding $1 billion in Q1 2026 and TTR revenues exceeding $1 billion in Q2 2026.
• GAAP Net income of $164.5 million, a substantial improvement from a net loss in the prior year.
• Non-GAAP Net income of $251.8 million, demonstrating strong operational performance.
• Cash, cash equivalents, and marketable securities increased to $3.3 billion, providing a strong liquidity position.
• Advancement of pipeline with Phase 2 initiations for ALN-6400 (von Willebrand Disease) and mivelsiran (Down Syndrome-associated Alzheimer's Disease).

Negatives

• Revised full-year 2026 TTR net product revenue guidance downwards to $4,200 $4,500 million from $4,400 $4,700 million.
• The decrease in guidance is due to moderated second-line demand for AMVUTTRA in the U.S. ATTR-CM market after initial pent-up demand was met.
• Net revenues from collaborations decreased by 23% due to lower revenue from the Regeneron collaboration.
• Cost of goods sold as a percentage of net product revenues increased to 25.4% from 21.1% in the prior year quarter.

Risks

• The company's ability to successfully launch, market, and sell approved products globally, including AMVUTTRA.
• The pre-clinical and clinical results for product candidates, and the ability to demonstrate efficacy and safety.
• Actions and advice of regulatory agencies, and the ability to obtain and maintain regulatory approval, including favorable pricing and reimbursement.
• Delays, interruptions, or failures in the manufacture and supply of marketed products or product candidates.
• The ability to obtain, maintain, and protect intellectual property.
• The risk of future litigation and government investigations.
• Dependence on third parties for the development and commercialization of certain products.
• The evolving ATTR-CM market and the normalization of growth in second-line volume.

Future Outlook

The company has revised its full-year 2026 TTR net product revenue guidance downwards to $4,200 million $4,500 million, reflecting updated learnings from the ATTR-CM market launch. The guidance for Total Rare net product revenues remains $500 million $600 million. Net revenues from collaborations and royalties are projected to be $575 million $625 million. Non-GAAP R&D and SG&A expenses are reiterated at $2,700 million $2,800 million.

Management Comments

• "During the first half of 2026, we continued to meaningfully advance our business, generating over $1 billion in quarterly product revenues for the first time in our history during the first quarter and, building on that momentum, over $1 billion in TTR revenues during the second quarter."
• "These results underscore the growing leadership and global impact of our TTR franchise in transforming outcomes for patients with ATTR amyloidosis, with AMVUTTRA being the only product approved for the full spectrum of the disease."
• "We have lowered our TTR product sales guidance for full-year 2026 to reflect learnings from the initial phase of our launch in the evolving ATTR-CM market, in particular the normalization of growth in second line volume after satisfying pent-up demand from patients waiting for a new therapy."
• "Given the strong foundation we have established and continued growth in ATTR-CM diagnosis and treatment, we remain confident in the trajectory of our ongoing ATTR-CM launch and are continuing to invest robustly in this franchise, as we bring AMVUTTRA to more patients and establish it as a foundational therapy."
• "During the second quarter, we also continued to advance our high-value pipeline with the initiation of two Phase 2 studies, ALN-6400 in von Willebrand disease and mivelsiran in Down syndrome-associated Alzheimers disease, while progressing multiple additional programs toward important clinical readouts later this year."
• "Together, these achievements demonstrate our continued progress against our Alnylam 2030 strategy and our commitment to creating long-term value through scientific innovation and patient impact."

Industry Context

StockSavvy.ai notes that Alnylam's performance in Q2 2026 highlights the continued strength of its RNAi therapeutics, particularly in the TTR amyloidosis market. The downward revision in guidance, while a point of caution, is attributed to market dynamics rather than a fundamental issue with the product's efficacy, a common occurrence in competitive and rapidly evolving therapeutic areas. The company's strategic collaborations in AI and expansion into new disease areas signal a proactive approach to innovation within the biopharmaceutical sector.

Comparison to Industry Standards

• Alnylam's reported 74% year-over-year growth in total net product revenues for Q2 2026 significantly outpaces the average growth rates seen in the broader biotechnology sector, which often hovers in the low to mid-teens for established companies.
• The 89% growth in TTR net product revenues is particularly strong, indicating market leadership in this niche, which is crucial for rare disease treatments where penetration and patient identification are key drivers.
• The company's investment in R&D, representing a substantial portion of its operating expenses, aligns with industry best practices for companies focused on innovation and pipeline development, though the absolute dollar amount is high due to the scale of their clinical trials.
• The strategic use of AI in drug discovery, through collaborations with companies like Inceptive, reflects a growing trend across the pharmaceutical industry to leverage advanced technologies for faster and more efficient R&D.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for continued stock price appreciation driven by strong product sales and pipeline progress, tempered by the guidance revision.
• Patients: Continued access to and potential expansion of treatment options for ATTR amyloidosis (AMVUTTRA, ONPATTRO) and other rare diseases (GIVLAARI, OXLUMO).
• Healthcare Providers: Continued data generation and support for diagnosis and treatment of ATTR-CM, including AI-enabled screening approaches.
• Employees: Continued investment in R&D and commercial operations, supporting growth and innovation.

Next Steps

• Continue to invest robustly in the AMVUTTRA franchise.
• Bring AMVUTTRA to more patients and establish it as a foundational therapy.
• Present initial results from the Phase 1 clinical trial of ALN-HTT02 in patients with Huntington's disease at the EHDN Clinical Research Congress on October 23, 2026.
• Announce clinical data from additional pipeline programs in the second half of 2026, including results from Phase 1 and Phase 2 clinical trials of ALN-6400 and Phase 1 trial of ALN-2232.
• Continue to scale Marmot, Komodo's analytics AI platform, across key enterprise functions.
• Monitor the regulatory review of cemdisiran by the FDA and EMA, with a target action date in November 2026 for the FDA.

Key Dates

Recommendation

The company demonstrates strong revenue growth and operational improvements, but the downward revision in guidance for a key product line warrants a cautious approach. While the pipeline is advancing, the market's reaction to the revised outlook suggests a 'hold' position until further clarity on the ATTR-CM market dynamics and future growth trajectory emerges.

Keywords

RNAi therapeutics, ATTR amyloidosis, AMVUTTRA, ONPATTRO, GIVLAARI, OXLUMO, pharmaceuticals, financial results